Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective

被引：4

作者：

Kashefizadeh, Alireza ^{[1
]}

Kazemizadeh, Hossein ^{[2
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Shahid Labbafinejad Hosp, Dept Pulmonol, Tehran, Iran

[2] Univ Tehran Med Sci, Adv Thorac Res Ctr, Tehran, Iran

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2023年 / 25卷 / 02期

关键词：

Immunogenic cell death; Immunotherapy; Lung cancer; NSCLC; CALRETICULIN EXPOSURE; CHEMOTHERAPEUTIC-AGENTS; ADJUVANT CHEMOTHERAPY; MECHANISMS; APOPTOSIS; INDUCE; ACTIVATION; EXPRESSION; RESISTANT; AUTOPHAGY;

D O I：

10.1007/s12094-022-02949-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prevalence of non-small-cell lung cancer (NSCLC) is rising every year all around the world. The interaction between cancer cells and the tumor microenvironment (TME) is a crucial factor in determining the development of human neoplasms. Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly characterized entity caused by various cancer treatments. The induction of ICD has the potential to change TME and the recruitment of tumor-infiltrating lymphocytes (TILs), and the coupling of ICD-inducers and other therapeutic approaches can have a synergistic role in boosting anticancer impacts. The purpose of this study is to review the studies in the field of NSCLC using ICD-inducers as a treatment strategy or as a combination therapy. This review provide for researches a better view of what has been done so far and the challenges they face in the future.

引用

页码：316 / 322

页数：7

共 86 条

[1] Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Tribodet, H. ;

Burdett, S. ;

Stewart, L. A. ;

Tierney, J. F. ;

Stephens, R. J. ;

Arriagada, R. ;

Higgins, J. P. ;

Johnson, D. H. ;

van Meerbeeck, J. ;

Parmar, M. K. B. ;

Souhami, R. L. ;

Bergman, B. ;

Dautzenberg, B. ;

Douillard, J. Y. ;

Dunant, A. ;

Endo, C. ;

Girling, D. J. ;

Imaizumi, M. ;

Kato, H. ;

Keller, S. M. ;

Kimura, H. ;

Knuuttila, A. ;

Kodama, K. ;

Komaki, R. ;

Kris, M. G. ;

Lad, T. ;

Mineo, T. ;

Park, J. H. ;

Piantadosi, S. ;

Pyrhonen, S. ;

Rosell, R. ;

Scagliotti, G. V. ;

Seymour, L. W. ;

Shepherd, F. A. ;

Spiro, S. G. ;

Strauss, G. M. ;

Sylvester, R. ;

Tada, H. ;

Tanaka, F. ;

Torri, V. ;

Wada, H. ;

Waller, D. ;

Xu, G. C. .

LANCET, 2010, 375 (9722) :1267-1277

[2] eIF2α phosphorylation: A hallmark of immunogenic cell death [J].

Bezu, Lucillia ;

Sauvat, Allan ;

Humeau, Juliette ;

Leduc, Marion ;

Kepp, Oliver ;

Kroemer, Guido .

ONCOIMMUNOLOGY, 2018, 7 (06)

[3] Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].

Bracci, L. ;

Schiavoni, G. ;

Sistigu, A. ;

Belardelli, F. .

CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25

[4] Decoding cell death signals in liver inflammation [J].

Brenner, Catherine ;

Galluzzi, Lorenzo ;

Kepp, Oliver ;

Kroemer, Guido .

JOURNAL OF HEPATOLOGY, 2013, 59 (03) :583-594

[5] Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells [J].

Bugaut, Helene ;

Bruchard, Melanie ;

Berger, Helene ;

Derangere, Valentin ;

Odoul, Ludivine ;

Euvrard, Romain ;

Ladoire, Sylvain ;

Chalmin, Fanny ;

Vegran, Frederique ;

Rebe, Cedric ;

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Mignot, Gregoire .

PLOS ONE, 2013, 8 (06)

[6] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Tierney, Jayne F. ;

Auperin, Anne ;

Le Pechoux, Cecile ;

Le Chevalier, Thierry ;

Pignon, Jean-Pierre .

LANCET, 2014, 383 (9928) :1561-1571

[7] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death [J].

Casares, N ;

Pequignot, MO ;

Tesniere, A ;

Ghiringhelli, F ;

Roux, S ;

Chaput, N ;

Schmitt, E ;

Hamai, A ;

Hervas-Stubbs, S ;

Obeid, M ;

Coutant, F ;

Métivier, D ;

Pichard, E ;

Aucouturier, P ;

Pierron, G ;

Garrido, C ;

Zitvogel, L ;

Kroemer, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1691-1701

[8] Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells [J].

Cirone, Mara ;

Garufi, Alessia ;

Di Renzo, Livia ;

Granato, Marisa ;

Faggioni, Alberto ;

D'Orazi, Gabriella .

ONCOIMMUNOLOGY, 2013, 2 (09)

[9] Activation of dendritic cells by tumor cell death [J].

Cirone, Mara ;

Di Renzo, Livia ;

Lotti, Lavinia V. ;

Conte, Valeria ;

Trivedi, Pankaj ;

Santarelli, Roberta ;

Gonnella, Roberta ;

Frati, Luigi ;

Faggioni, Alberto .

ONCOIMMUNOLOGY, 2012, 1 (07) :1218-1219

[10] Primary Effusion Lymphoma Cell Death Induced by Bortezomib and AG 490 Activates Dendritic Cells through CD91 [J].

Cirone, Mara ;

Di Renzo, Livia ;

Lotti, Lavinia Vittoria ;

Conte, Valeria ;

Trivedi, Pankaj ;

Santarelli, Roberta ;

Gonnella, Roberta ;

Frati, Luigi ;

Faggioni, Alberto .

PLOS ONE, 2012, 7 (03)

← 1 2 3 4 5 6 7 8 9 →